MAP2K7 and melanoma: A recent report has suggested that targeting mTOR signaling overcame acquired resistance in BRAF-mutant melanoma (Wang et al., 2021), implying targeting signaling pathways bypass MAPK/MEK signaling to bring out great improvement.